Anyone think it was oddthat the Water Tower Research paid for piece focused on cancer and basically overlooked NASH? Is there a reason (besides the FDA meeting and working to get the EMA on board) we don't know about for pushing the start of the NASH trial out to the third quarter? Is the reason they sold equity and warrants at a zero value for NASH because the company does not believe in their NASH plans and might deep six it if the early cancer data looks really promising? Just trying to connect some dots but may be trying to hard to do so.